Tarsus Pharmaceuticals Inc has a consensus price target of $51.75 based on the ratings of 8 analysts. The high is $65 issued by Raymond James on October 8, 2021. The low is $30 issued by Goldman Sachs on February 29, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Barclays, and Oppenheimer on May 13, 2024, May 10, 2024, and May 9, 2024, respectively. With an average price target of $60.67 between HC Wainwright & Co., Barclays, and Oppenheimer, there's an implied 123.53% upside for Tarsus Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/13/2024 | Buy Now | 124.76% | HC Wainwright & Co. | Oren Livnat | $57 → $61 | Maintains | Buy | Get Alert |
05/10/2024 | Buy Now | 121.08% | Barclays | Balaji Prasad | $50 → $60 | Maintains | Overweight | Get Alert |
05/09/2024 | Buy Now | 124.76% | Oppenheimer | Francois Brisebois | $59 → $61 | Maintains | Outperform | Get Alert |
03/06/2024 | Buy Now | 62.12% | Jefferies | Anthony Petrone | $30 → $44 | Maintains | Buy | Get Alert |
02/29/2024 | Buy Now | 10.54% | Goldman Sachs | Andrea Tan | $19 → $30 | Maintains | Neutral | Get Alert |
02/28/2024 | Buy Now | 110.02% | HC Wainwright & Co. | Oren Livnat | $50 → $57 | Maintains | Buy | Get Alert |
02/28/2024 | Buy Now | 84.23% | Barclays | Balaji Prasad | $40 → $50 | Maintains | Overweight | Get Alert |
02/28/2024 | Buy Now | 117.39% | Oppenheimer | Francois Brisebois | $55 → $59 | Reiterates | Outperform → Outperform | Get Alert |
11/20/2023 | Buy Now | -29.99% | Goldman Sachs | Andrea Tan | → $19 | Initiates | → Neutral | Get Alert |
11/10/2023 | Buy Now | 84.23% | HC Wainwright & Co. | Oren Livnat | $42 → $50 | Maintains | Buy | Get Alert |
09/11/2023 | Buy Now | 80.55% | Guggenheim | Eddie Hickman | $46 → $49 | Maintains | Buy | Get Alert |
08/14/2023 | Buy Now | 69.49% | Guggenheim | Eddie Hickman | → $46 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | Buy Now | 54.75% | HC Wainwright & Co. | Oren Livnat | $50 → $42 | Maintains | Buy | Get Alert |
07/26/2023 | Buy Now | 84.23% | HC Wainwright & Co. | Oren Livnat | $44 → $50 | Maintains | Buy | Get Alert |
07/18/2023 | Buy Now | 62.12% | William Blair | — | → $44 | Initiates | → Outperform | Get Alert |
06/26/2023 | Buy Now | 62.12% | HC Wainwright & Co. | Oren Livnat | $40 → $44 | Maintains | Buy | Get Alert |
06/16/2023 | Buy Now | 54.75% | Guggenheim | Eddie Hickman | $40 → $42 | Maintains | Buy | Get Alert |
05/18/2023 | Buy Now | — | Guggenheim | Eddie Hickman | — | Initiates | → Buy | Get Alert |
05/08/2023 | Buy Now | 58.44% | Oppenheimer | Francois Brisebois | → $43 | Reiterates | → Outperform | Get Alert |
03/15/2023 | Buy Now | 47.38% | HC Wainwright & Co. | Oren Livnat | → $40 | Reiterates | → Buy | Get Alert |
08/01/2022 | Buy Now | 47.38% | Barclays | Balaji Prasad | → $40 | Initiates | → Overweight | Get Alert |
12/21/2021 | Buy Now | 47.38% | HC Wainwright & Co. | Oren Livnat | → $40 | Initiates | → Buy | Get Alert |
11/23/2021 | Buy Now | 102.65% | Oppenheimer | Francois Brisebois | — | Initiates | → Outperform | Get Alert |
10/08/2021 | Buy Now | 139.5% | Raymond James | Dane Leone | — | Maintains | Strong Buy | Get Alert |
The latest price target for Tarsus Pharmaceuticals (NASDAQ:TARS) was reported by HC Wainwright & Co. on May 13, 2024. The analyst firm set a price target for $61.00 expecting TARS to rise to within 12 months (a possible 124.76% upside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ:TARS) was provided by HC Wainwright & Co., and Tarsus Pharmaceuticals maintained their buy rating.
There is no last upgrade for Tarsus Pharmaceuticals
There is no last downgrade for Tarsus Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a maintained with a price target of $57.00 to $61.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $27.14, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.